<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238065</url>
  </required_header>
  <id_info>
    <org_study_id>GuangzhouShijingMS</org_study_id>
    <nct_id>NCT04238065</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Caterna Virtual Reality Facilitating Treatment in Children With Amblyopia</brief_title>
  <acronym>VRTA</acronym>
  <official_title>A Phase 3 Randomized, Single-blind, Multicenter, Clinical Control Study to Evaluate the Efficacy and Safety of Caterna Virtual Reality Facilitating Treatment Patients With Amblyopia in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Shijing Medical Software</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Beijing University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan Ophthalmic Center, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou Shijing Medical Software</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It aims to find the effectiveness and the safety of Virtual Reality (Caterna, DOBOSO, item
      code: SJ-VRS2018) to facilitate amblyopia treatment combining spectacles and occlusion. And
      it also aims to test whether amblyopia treatment outcomes with spectacles, occlusion and VR
      are significant better than those without VR, but with spectacles and occlusion.

      The experiment arm is designed to use the Caterna VR to treat amblyopia for total consistent
      13 weeks, 3 times per week, while the control arm is not.

      Both arms are best optical correction and with patch the non-amblyopia eye 2 hours or 6 hours
      per day.

      All eyes are followed up for total 13 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The amblyopia eye will see the video content from Caterna VR a little bit earlier (12 ms)
      than the other non-amblyopia eye.

      Also, the illumination and contrast are both adjusted to balance 2 eyes' clarity.

      One VR treatment sequence is 30 minutes with 5 minutes break in the middle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One arm receive VR treatment while the other arm does not. Both arms get best optical correction and 2 hours (for mild and moderate amblyopia）patch or 6 hours (for severe amblyopia) patch their non-amblyopia eyes.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Research centers are used as a stratification factor. The researchers include subjects in the trial group or control group based on randomized envelopes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of amblyopia treatment with VR</measure>
    <time_frame>13 weeks</time_frame>
    <description>General Effectiveness=Number of both cured eyes and effective eyes from total number×100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of 8 weeks' VR amblyopia treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>General Effectiveness=Number of both cured eyes and effective eyes from total number×100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of 4 weeks' VR amblyopia treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>General Effectiveness=Number of both cured eyes and effective eyes from total number×100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stereopsis: distance and near, respectively</measure>
    <time_frame>13 weeks</time_frame>
    <description>Ratio of stereopsis perception=(Number of stereopsis perception /Total number)*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity function(CSF)</measure>
    <time_frame>13 weeks</time_frame>
    <description>Difference between those final CSF and baseline CSF</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Severe Adverse Event Number</measure>
    <time_frame>13 weeks</time_frame>
    <description>Total number of Severe Adverse Event</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Amblyopia</condition>
  <arm_group>
    <arm_group_label>VR treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The arm will use the virtual reality headset reproduces dynamic video content with perceptual learning and binocular perception (including stereopsis) that is visually perceived a little bit faster, brighter, and higher contrast to the amblyopia eyes .
The each VR therapy length is 30 minutes with 5 minute break after 15 minutes' therapy sequence, 3 times per week, total 13 weeks.
All amblyopia eyes are best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm of amblyopia eyes are all best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity.
No VR therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Caterna Virtual Reality</intervention_name>
    <description>Vivid interactive games of perceptual learning content, with artificial intelligent sound and scores to feedback vision and actions results, which can be connected to the supervision of cellphone software&quot;Wechat&quot; to upload vision acuity and choose 2 eyes' video output automaticly.</description>
    <arm_group_label>VR treatment</arm_group_label>
    <other_name>SJ-VRS2018</other_name>
    <other_name>DOBOSO VR</other_name>
    <other_name>Vision Therapy Software</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spectacles(Best optical corrected distance vision)</intervention_name>
    <description>Each eye has best corrected vision spectacles with best corrected optical lens.</description>
    <arm_group_label>VR treatment</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>Optical correction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patch</intervention_name>
    <description>2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia</description>
    <arm_group_label>VR treatment</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>Occlusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages from 4~12 years old (including 4 years or 12 years old）；

          2. According to the Chinese Medical Association Ophthalmology branch: Strabismus and
             Pediatric Ophthalmology Experts &quot;Consensus of Amblyopia Diagnosis &quot; (2011) as the
             standard to be diagnosed as amblyopia with abnormal vision than that of age-based
             norms, that is, caused by abnormal visual development due to strabismus, uncorrected
             refractive error or form deprivation, the best corrected vision acuity of single eye
             or both eyes below age-based norms; Or 2 eyes' vision acuity difference larger than 2
             lines or more. The normal minimum limit of vision acuity for children of different
             ages are as the followings: The normal minimum limit of vision acuity for children
             aged 4 to 5 years is 0.5 (decimal vision acuity); And the normal minimum limit of
             vision acuity for children aged 6 and over is 0.7(decimal vision acuity).

          3. The subject's supervision is fully understand the purpose of the trial and sign an
             informed consent form; And the subject can cooperate with the whole treatment and
             related eye examinations。 -

        Exclusion Criteria:

          1. Subjects suffered from tumors, heart disease, hypertension (blood pressure top
             limitation of children aged 4 to 6 years: 110/70 mmHg, blood pressure top limitation
             of children aged 7 to 12 years: 120/80 mmHg), or epilepsy;

          2. The subject has implanted electronic devices, such as pacemakers, etc.

          3. The subject had or has a mental illness;

          4. Any eye of the subject due to keratitis, conjunctivitis, internal turning eyelashes
             and other diseases leading to photophobia or continuing tears;

          5. Subject suffered from vertigo, acrophobia or traumatic brain lesions;

          6. The subject's eye has congenital glaucoma, congenital ptosis, dacryocystitis, trauma
             and other significant vision related lesions;

          7. Subject received a masking therapy or a treatment instrument for amblyopia treatment
             before joining this study;

          8. The subject participated in other clinical trials before joining this study;

          9. For safety reasons or for the benefit of patients, the researchers believe that the
             patient should not participate in other conditions, such as suffering from a certain
             severe heart, liver or kidney disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohong Liu</last_name>
    <role>Study Director</role>
    <affiliation>Guangzhou Shijing Medical Software</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mosheng Zhou</last_name>
    <role>Study Chair</role>
    <affiliation>Guangzhou Shijing Medical Software</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Qiu, MD</last_name>
    <phone>+8618510386815</phone>
    <email>qiukk@topeye.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Taylor Zhu, MS</last_name>
    <phone>+8613060934107</phone>
    <email>zhuda@topeye.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the first affiliated hospital of Beijing University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoqing Li, MD, PhD</last_name>
      <phone>+861083572336</phone>
      <email>fangfeilee8@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yiwen Cao, MD, PhD</last_name>
      <phone>+8613269978261</phone>
      <email>ertongyanke@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaoqing Li, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Wen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yiwen Cao, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Shijing Medical Software Co., Ltd.</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic center, Sun Yat-sen University</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Yan, MD, PhD</last_name>
      <phone>+862087330484</phone>
      <email>yan2011@tom.com</email>
    </contact>
    <investigator>
      <last_name>Jianhua Yan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tao Shen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hu Liu, MD, PhD</last_name>
      <phone>+8613952091066</phone>
      <email>liuhu66@163.com</email>
    </contact>
    <investigator>
      <last_name>Hu Liu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhenhua Leng, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui Zhu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Repka MX, Beck RW, Holmes JM, Birch EE, Chandler DL, Cotter SA, Hertle RW, Kraker RT, Moke PS, Quinn GE, Scheiman MM; Pediatric Eye Disease Investigator Group. A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol. 2003 May;121(5):603-11.</citation>
    <PMID>12742836</PMID>
  </results_reference>
  <results_reference>
    <citation>Holmes JM, Kraker RT, Beck RW, Birch EE, Cotter SA, Everett DF, Hertle RW, Quinn GE, Repka MX, Scheiman MM, Wallace DK; Pediatric Eye Disease Investigator Group. A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. Ophthalmology. 2003 Nov;110(11):2075-87.</citation>
    <PMID>14597512</PMID>
  </results_reference>
  <results_reference>
    <citation>Scheiman MM, Hertle RW, Beck RW, Edwards AR, Birch E, Cotter SA, Crouch ER Jr, Cruz OA, Davitt BV, Donahue S, Holmes JM, Lyon DW, Repka MX, Sala NA, Silbert DI, Suh DW, Tamkins SM; Pediatric Eye Disease Investigator Group. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol. 2005 Apr;123(4):437-47.</citation>
    <PMID>15824215</PMID>
  </results_reference>
  <results_reference>
    <citation>Yazdani N, Sadeghi R, Momeni-Moghaddam H, Zarifmahmoudi L, Ehsaei A, Barrett BT. Part-time versus full-time occlusion therapy for treatment of amblyopia: A meta-analysis. J Curr Ophthalmol. 2017 Mar 6;29(2):76-84. doi: 10.1016/j.joco.2017.01.006. eCollection 2017 Jun. Review.</citation>
    <PMID>28626815</PMID>
  </results_reference>
  <results_reference>
    <citation>Jin H, Yi JL, Xie H, Xiao F, Wang WJ, Shu XM, Xu YL, Chen SL, Ye WX. [A study on visual development among preschool children]. Zhonghua Yan Ke Za Zhi. 2011 Dec;47(12):1102-6. Chinese.</citation>
    <PMID>22336120</PMID>
  </results_reference>
  <results_reference>
    <citation>He MG. [The quality of epidemiological research on pediatric refractive error and amblyopia in China needs to be improved]. Zhonghua Yan Ke Za Zhi. 2017 Jan 11;53(1):3-6. doi: 10.3760/cma.j.issn.0412-4081.2017.01.002. Review. Chinese.</citation>
    <PMID>28162193</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 18, 2020</study_first_submitted>
  <study_first_submitted_qc>January 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amblyopia; Virtual Reality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

